Skip to main content
. 2017 Dec 22;109(2):264–271. doi: 10.1111/cas.13455

Table 1.

The chemical structures and characteristics of key components or related compounds in chemotherapeutic drugs currently approved for the treatment of metastatic colorectal cancer patients

Nomenclature 5‐Fluorouracil (5‐FU) Oxaliplatin Camptothecin (CPT) Trifluridine (FTD)
Chemical structural formula graphic file with name CAS-109-264-g004.jpg graphic file with name CAS-109-264-g005.jpg graphic file with name CAS-109-264-g006.jpg graphic file with name CAS-109-264-g007.jpg
Compositional formula C4H3FN2O2 = 130.08 C8H14N2O4Pt = 397.29 C20H16N2O4 = 348.36 C10H11F3N2O5 = 296.20
Characteristics Uracil analogue DNA crosslinker Topoisomerase I (Topo I) inhibitor Nucleoside analogue. A key component of trifluridine/tipiracil (TFTD/TAS‐102)
RNA incorporation Cell cycle arrest at G1 phase via p53‐dependent miR‐34a upregulation Topo I‐cc (covalent complex) becomes obstacle of replication and triggers 1‐ended dsDNA breaks DNA incorporation
dTTP starvation via thymidylate synthase inhibition by fluorodeoxyuridine monophosphate Irinotecan is an analogue of CPT Cellular senescence‐like growth arrest dependent on p53